Shanghai Fosun Pharmaceutical(02196) announced the results for the first three quarters of 2021, realizing revenue of about 27.048 billion yuan (the same as below), an increase of 22.38% over the same period last year; net profit belonging to shareholders of listed companies was about 3.565 billion yuan, an increase of 43.8% over the same period last year; net profit belonging to shareholders of listed companies after deducting non-recurring gains and losses was about 2.475 billion yuan, an increase of 20.19% over the same period last year; basic earnings per share were 1.39 yuan.

In the third quarter of 2021, the group achieved an operating income of 10.096 billion yuan, an increase of 25.03 percent over the same period last year, and a net profit of 1.082 billion yuan belonging to shareholders of listed companies, an increase of 41.62 percent over the same period last year. The net profit belonging to shareholders of listed companies after deducting non-recurring profits and losses was 905 million yuan, an increase of 19.84 percent over the same period last year. Basic earnings per share is 0.42 yuan.

The announcement said that the increase in net profit was attributed to the continued volume of new products such as Hanlikang, Hanquyou and Su Kexin, which promoted income growth and product structure optimization; the contribution of mRNA COVID-19 Vaccine in Hong Kong, Macao and Taiwan; and the increase in the fair value of financial assets such as BioNTech.